| Mar 12 |
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
|
| Mar 6 |
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
|
| Feb 29 |
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
|
| Feb 22 |
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
|
| Feb 21 |
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"
|
| Feb 13 |
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
|
| Feb 13 |
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
|
| Jan 29 |
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
|
| Jan 18 |
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
|
| Jan 16 |
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
|
